Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

Background. The global emergence of carbapenem-resistant Enterobacteriaceae highlights the urgent need to reduce carbapenem dependence. The phase 3 RECAPTURE program compared the efficacy and safety of ceftazidime-avibactam and doripenem in patients with complicated urinary tract infection (cUTI), i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagenlehner, Florian M., Sobel, Jack D., Newell, Paul, Armstrong, Jon, Huang, Xiangning, Stone, Gregory G., Yates, Katrina, Gasink, Leanne B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4996135/
https://www.ncbi.nlm.nih.gov/pubmed/27313268
http://dx.doi.org/10.1093/cid/ciw378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4996135/
https://www.ncbi.nlm.nih.gov/pubmed/27313268
http://dx.doi.org/10.1093/cid/ciw378

Ejemplares similares